These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31854307)

  • 21. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
    Grosso G; Vikerfors A; Woodhams B; Adam M; Bremme K; Holmström M; Ågren A; Eelde A; Bruzelius M; Svenungsson E; Antovic A
    Thromb Res; 2017 Oct; 158():168-173. PubMed ID: 28669410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications.
    Antovic JP; Yngen M; Ostenson CG; Antovic A; Wallen HN; Jorneskög G; Blombäck M
    Blood Coagul Fibrinolysis; 2003 Sep; 14(6):551-6. PubMed ID: 12960608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
    Akinci B; Comlekci A; Yener S; Demir T; Ozcan MA; Bayraktar F; Yesil S
    Endocr J; 2007 Aug; 54(4):593-9. PubMed ID: 17690487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
    Zorio E; Castelló R; Falcó C; España F; Osa A; Almenar L; Aznar J; Estellés A
    Br J Haematol; 2003 Sep; 122(6):958-65. PubMed ID: 12956767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement.
    Akinci B; Comlekci A; Ali Ozcan M; Demir T; Yener S; Demirkan F; Yuksel F; Yesil S
    Endocr J; 2007 Feb; 54(1):45-52. PubMed ID: 17090955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?
    Antovic JP; Rafik Hamad R; Antovic A; Blombäck M; Bremme K
    Thromb Haemost; 2002 Oct; 88(4):644-7. PubMed ID: 12362237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
    Cibor D; Owczarek D; Butenas S; Salapa K; Mach T; Undas A
    World J Gastroenterol; 2017 Jul; 23(26):4796-4805. PubMed ID: 28765701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A.
    Antovic J; Schulman S; Eelde A; Blombäck M
    Haemophilia; 2001 Nov; 7(6):557-60. PubMed ID: 11851753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma levels of unactivated thrombin activatable fibrinolysis inhibitor (TAFI) are down-regulated in young adult women: analysis of a normal Japanese population.
    Akatsu H; Ishiguro M; Ogawa N; Kanesaka T; Okada N; Yamamoto T; Campbell W; Okada H
    Microbiol Immunol; 2007; 51(5):507-17. PubMed ID: 17579260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On-demand but not prophylactic treatment with FVIII concentrate increase thrombin activatable fibrinolysis inhibitor activation in severe haemophilia A patients.
    Mikovic D; Woodhams BJ; Holmström M; Elezovic I; Antovic A; Mobarrez F; Elfvinge P; Antovic JP
    Int J Lab Hematol; 2012 Feb; 34(1):35-40. PubMed ID: 21707936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD.
    Owczarek D; Undas A; Foley JH; Nesheim ME; Jabłonski K; Mach T
    J Crohns Colitis; 2012 Feb; 6(1):13-20. PubMed ID: 22261523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced thrombin activatable fibrinolysis inhibitor and enhanced proinflammatory cytokines in acute coronary syndrome.
    Pang H; Zhang C; Liu F; Gong X; Jin X; Su C
    Med Intensiva; 2017 Nov; 41(8):475-482. PubMed ID: 28038785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Higher thrombin activatable fibrinolysis inhibitor levels are associated with inflammation in attack-free familial Mediterranean fever patients.
    Bavbek N; Ceri M; Akdeniz D; Kargili A; Duranay M; Erdemli K; Akcay A; Guz G
    Ren Fail; 2014 Jun; 36(5):743-7. PubMed ID: 24580410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
    Antovic JP; Schulman S; An SS; Greenfield RS; Blombäck M
    Scand J Clin Lab Invest; 2004; 64(8):745-51. PubMed ID: 15719893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels.
    Santamaría A; Oliver A; Borrell M; Mateo J; Belvis R; Martí-Fábregas J; Ortín R; Tirado I; Souto JC; Fontcuberta J
    Stroke; 2003 Oct; 34(10):2387-91. PubMed ID: 12947154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis.
    Lisman T; Leebeek FW; Mosnier LO; Bouma BN; Meijers JC; Janssen HL; Nieuwenhuis HK; De Groot PG
    Gastroenterology; 2001 Jul; 121(1):131-9. PubMed ID: 11438502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Occurrence of Thrombosis in Inflammatory Bowel Disease Is Reflected in the Clot Lysis Profile.
    Bollen L; Vande Casteele N; Peeters M; Van Assche G; Ferrante M; Van Moerkercke W; Declerck P; Vermeire S; Gils A
    Inflamm Bowel Dis; 2015 Nov; 21(11):2540-8. PubMed ID: 26313696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins. Pharmacologic implications.
    Florian-Kujawski M; Hoppensteadt D; Maddineni J; Ziegler H; Fareed J
    Int Angiol; 2004 Dec; 23(4):346-54. PubMed ID: 15767980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Change in plasma a disintegrin and metalloprotease with thrombospondin type-1 repeats-13 and von Willebrand factor levels in venous thromboembolic patients.
    Karakaya B; Tombak A; Serin MS; Tiftik N
    Hematology; 2016 Jun; 21(5):295-9. PubMed ID: 26872106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension.
    Yaoita N; Satoh K; Satoh T; Sugimura K; Tatebe S; Yamamoto S; Aoki T; Miura M; Miyata S; Kawamura T; Horiuchi H; Fukumoto Y; Shimokawa H
    Arterioscler Thromb Vasc Biol; 2016 Jun; 36(6):1293-301. PubMed ID: 27102961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.